Oswaldo Hernández‐González

Autonomous University of San Luis Potosí

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Diana Patricia Portales‐Pérez

Autonomous University of San Luis Potosí

Miguel Ernesto Martínez-Leija

Autonomous University of San Luis Potosí

Rosa del Carmen Milán‐Segovia

Autonomous University of San Luis Potosí

Víctor Manuel González-Quintana

Hospital de Especialidades

Alma Grisel Díaz-Martínez

Mexican Social Security Institute

Eduardo Alberto González Escudero

Instituto Nacional de Cardiologia

Lucero Sánchez-Huerta

Mexican Social Security Institute

Daniel Zavala-Reyes

Autonomous University of San Luis Potosí

Susana Barrera-Hernández

Hospital de Especialidades

Gerardo Santiago-Jiménez

Instituto Politécnico Nacional

Cooperative Institutions

Autonomous University of San Luis Potosí

Mexican Social Security Institute

Centro Medico Nacional Siglo XXI

Hospital de Especialidades

Instituto Politécnico Nacional

Universidad Nacional Autónoma de México

Polytechnic University of San Luis Potosí

Hospital Central Dr. Ignacio Morones Prieto

Institute for Scientific and Technological Research

Center for Research and Advanced Studies of the National Polytechnic Institute

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Arylamines N-acetyltransferases 1 and 2: physiology, genetics and epigenetics

Gaceta Médica de México (2025)

Oswaldo Hernández‐González Miguel Ernesto Martínez-Leija Víctor A. Paz-Rodríguez Diana Patricia Portales‐Pérez

Arylamine N-Acetyltransferases NAT1 and NAT2 are enzymes mainly known for participating in phase II of the detoxification process. Both enzymes are present in various organs, such as the liver, intestine, lung, skin, and immune cells. Recent stud-ies implicate its possible role in carcinogenesis or cell metabolism; The catalytic activity, representing a substantial influence on the cellular concentration of its Acetyl Coenzyme A cofactor, can influence multiple cellular processes, depending on its cytoplasmic concentration. A review was carried out in the databases ENCODE and PubMed to identify information of interest on the epigenetics of NAT1 and NAT2 promoters and reports proposing the possible mechanisms involved in the diseases under study. The effect of NAT1 on folate metabolism has led to it being proposed as a possible epigenetic regulator.

Acetyltransferases

10.24875/gmm.m24000946

Cite

Citations (0)

SUN-036 SLC16A11 Gene Expression In Mothers With And Without Gestational Diabetes And Their Offspring Umbilical Cord Blood.

Journal of the Endocrine Society (2019)

Daniel Marrero‐Rodríguez Manuel Sevilla-Domingo Rita A. Gómez‐Díaz Víctor Mauricio Huerta-Padilla Keiko Taniguchi‐Ponciano

Cord blood

10.1210/js.2019-sun-036

Cite

Citations (0)

Genetic polymorphisms of arylamine N-acetyltransferases 1 and 2 and the likelihood of developing pediatric acute lymphoblastic leukemia

Leukemia & lymphoma/Leukemia and lymphoma (2017)

Oswaldo Hernández‐González Juan José Ortiz-Zamudio Cristian Jazmín Rodríguez‐Pinal Ildemar Alvarado-Morales Verónica Martínez-Jiménez

Acute lymphoblastic leukemia (ALL) is one of the main causes of death in children and is associated with both genetic susceptibility and environmental factors. Genes encoding the arylamine N-acetyltransferases 1 and 2 (NAT1 and NAT2) isoenzymes are highly polymorphic among populations. Single-nucleotide polymorphism analysis was performed by real-time polymerase chain reaction from the genomic DNA of 225 healthy subjects and 57 children with ALL diagnoses. Significant associations were found between the development of ALL and the presence of the haplotypes NAT1*3 (Odds ratio [OR], 2.1), NAT1*4 (OR, 1.92), NAT2*6B (OR, 3.30), NAT2*6J (OR, 3.25) and NAT2*7A (OR, 2.45) and the NAT1 rapid (OR, 6.69) and NAT2 slow phenotypes (OR, 2.95). Our results indicate that haplotypes that provide rapid NAT1 and slow NAT2 acetylating phenotypes may influence the development of ALL in children.

Arylamine N-acetyltransferase

10.1080/10428194.2017.1406090

Cite

Citations (9)

The role of arylamine N-acetyltransferases in chronic degenerative diseases: Their possible function in the immune system

Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2022)

Oswaldo Hernández‐González Diana Judith Herrera-Vargas Miguel Ernesto Martínez-Leija Daniel Zavala-Reyes Diana Patricia Portales‐Pérez

Acetyltransferases

10.1016/j.bbamcr.2022.119297

Cite

Citations (8)

Arilaminas N-acetiltransferasas 1 y 2: fisiología, genética y epigenética

Gaceta Médica de México (2024)

Oswaldo Hernández‐González Miguel Ernesto Martínez-Leija Víctor A. Paz-Rodríguez Diana Patricia Portales‐Pérez

Las arilaminas N-acetiltransferasas NAT1 y NAT2 son enzimas principalmente conocidas por su participación en la fase II del proceso de detoxificación. Ambas enzimas se localizan en células inmunes y en diversos órganos como hígado, intestino, pulmón y piel. Estudios recientes sugieren su posible papel en el proceso de carcinogénesis o metabolismo celular. La actividad catalítica por su alta influencia en la concentración celular de su cofactor acetilcoenzima A puede participar en múltiples procesos celulares, dependiente de su concentración citoplasmática. Se realizó una búsqueda en las bases de datos ENCODE y PubMed para identificar información de interés sobre la epigenética de los promotores de NAT1 y NAT2, así como reportes sobre los posibles mecanismos implicados en las enfermedades de estudio. El efecto de NAT1 en el metabolismo del folato ha llevado a proponerlo como un posible regulador epigenético.

10.24875/gmm.24000125

Cite

Citations (0)

Asociación del estado hormonal con el riesgo cardiovascular evaluado por Globorisk en mujeres mexicanas

Gaceta Médica de México (2018)

Eduardo Alberto González Escudero Lourdes Basurto-Acevedo Susana Barrera-Hernández Alma Grisel Díaz-Martínez Lucero Sánchez-Huerta

Cardiovascular disease is the main cause of mortality worldwide. In women, its incidence increases at the sixth decade of life, coinciding with postmenopause. Whether this effect is due to menopause-related hormonal changes is not known.To evaluate the differences in cardiovascular risk in pre- and postmenopausal women by means of the Globorisk risk scale, the triglyceride/high-density lipoproteins cholesterol (Tg/HDL-C) ratio and metabolic syndrome (MS) criteria.Cross-sectional study that included 408 women from 40 to 60 years of age; anthropometric measurements and biochemical determinations were performed. The participants were classified as premenopausal and postmenopausal. Cardiovascular risk was assessed using the MS criteria, the Globorisk risk calculator and the Tg/HDL-C ratio.Postmenopausal women showed a significant increase in waist circumference, total cholesterol and triglycerides in comparison with premenopausal women. Significant associations were found between hormonal state and Globorisk measured cardiovascular risk (OR = 2.50; 95 % CI = 1.67-3.74) and the Tg/HDL-C ratio (OR = 1.66; 95 % CI = 1.09-2.52).Cardiovascular risk factors have a higher prevalence in postmenopause. The Globorisk scale and Tg/HDL-C ratio identify cardiovascular risk in postmenopausal women.La enfermedad cardiovascular es la principal causa de mortalidad en el mundo. En la mujer se incrementa en la sexta década de la vida, coincidiendo con la posmenopausia. Se desconoce si este efecto se debe a cambios hormonales relacionados con la menopausia.Evaluar diferencias del riesgo cardiovascular en mujeres pre y posmenopáusicas mediante la escala de riesgo Globorisk, el índice triglicéridos/c-HDL (Tg/c-HDL) y los criterios de síndrome metabólico (SM).Estudio transversal que incluyó a 408 mujeres de 40 a 60 años; se realizaron mediciones antropométricas y bioquímicas. Las participantes se clasificaron en premenopáusicas y posmenopáusicas. El riesgo cardiovascular se evaluó utilizando los criterios de SM, calculadora de riesgo Globorisk y el índice Tg/c-HDL.Las mujeres en etapa posmenopáusica presentaron incremento significativo en la circunferencia de cintura, de colesterol total y triglicéridos, en comparación con las mujeres premenopáusicas. Se encontraron asociaciones significativas del estado hormonal con el riesgo cardiovascular evaluado por Globorisk (RM = 2.50, IC 95 % = 1.67-3.74) y con el índice Tg/c-HDL (RM = 1.66, IC 95 % = 1.09-2.52).Los factores de riesgo cardiovascular tienen mayor prevalencia en la posmenopausia. La escala Globorisk y el índice Tg/c-HDL identifican el riesgo cardiovascular en la mujer posmenopáusica.

10.24875/gmm.18004104

Cite

Citations (1)

Association of hormonal state with cardiovascular risk evaluated with Globorisk in Mexican women

Gaceta Médica de México (2019)

Eduardo Alberto González Escudero Lourdes Basurto-Acevedo Susana Barrera-Hernández Alma Grisel Díaz-Martínez Lucero Sánchez-Huerta

Introducción: La enfermedad cardiovascular es la principal causa de mortalidad en el mundo.En la mujer se incrementa en la sexta década de la vida, coincidiendo con la posmenopausia.Se desconoce si este efecto se debe a cambios hormonales relacionados con la menopausia.Objetivo: Evaluar diferencias del riesgo cardiovascular en mujeres pre y posmenopáusicas mediante la escala de riesgo Globorisk, el índice triglicéridos/c-HDL (Tg/c-HDL) y los criterios de síndrome metabólico (SM).Métodos: Estudio transversal que incluyó a 408 mujeres de 40 a 60 años; se realizaron mediciones antropométricas y bioquímicas.Las participantes se clasificaron en premenopáusicas y posmenopáusicas.El riesgo cardiovascular se evaluó utilizando los criterios de SM, calculadora de riesgo Globorisk y el índice Tg/c-HDL.Resultados: Las mujeres en etapa posmenopáusica presentaron incremento significativo en la circunferencia de cintura, de colesterol total y triglicéridos, en comparación con las mujeres premenopáusicas.Se encontraron asociaciones significativas del estado hormonal con el riesgo cardiovascular evaluado por Globorisk (RM = 2.50, IC 95 % = 1.67-3.74)y con el índice Tg/c-HDL (RM = 1.66,IC 95 % = 1.09-2.52).Conclusión: Los factores de riesgo cardiovascular tienen mayor prevalencia en la posmenopausia.La escala Globorisk y el índice Tg/c-HDL identifican el riesgo cardiovascular en la mujer posmenopáusica.

Association (psychology)

10.24875/gmm.m19000204

Cite

Citations (0)

Quantification of pyrazinamide, isoniazid, acetyl‐isoniazid, and rifampicin by a high‐performance liquid chromatography method in human plasma from patients with tuberculosis

Journal of Separation Science (2020)

Oswaldo Hernández‐González Sergio Zarazúa José Ignacio Veytia‐Bucheli Marco Martín González‐Chávez Cristian Jazmín Rodríguez‐Pinal

Abstract The aim of this study was to establish and validate an alternative high‐performance liquid chromatography method for simultaneous quantification of pyrazinamide, isoniazid, acetyl‐isoniazid and rifampicin in plasma of patients under treatment for tuberculosis. The performed method was lineal ( r 2 > 0.99) in the range of 2.00–50.00 μg/mL for pyrazinamide, 0.50–20.00 μg/mL for both acetyl‐isoniazid and isoniazid, and 1.20–25.00 μg/mL for rifampicin. Precision and trueness were demonstrated with coefficient of variation < 15% and deviations < 15%, respectively, for quality controls samples. The lower limits of quantification were 2.00, 0.50, 0.50, and 1.20 μg/mL for pyrazinamide, isoniazid, acetyl‐isoniazid and rifampicin, respectively. The method was applied for the analysis of plasma from patients with tuberculosis. This method allowed ensuring reliable quantification of the target compounds and their pharmacokinetics parameters. In general, the mean values of maximum concentration of each antituberculosis drug were located within their respective reference therapeutic ranges. However, patients with sub‐therapeutic plasma concentrations of isoniazid and rifampicin were detected. This is the first analytical technique that simultaneously quantifies isoniazid, acetyl‐isoniazid, rifampicin, and pyrazinamide concentrations from plasma samples by high‐performance liquid chromatography with ultraviolet/visible. The proposed method could be applied for therapeutic drug monitoring and pharmacokinetics studies of the four compounds throughout the treatment of tuberculosis patients.

Pyrazinamide

Therapeutic Drug Monitoring

10.1002/jssc.202000672

Cite

Citations (14)

Fast microwave assisted bioreduction of aromatic aldehydes using Aloe vera: A green chemistry reaction

Revista latinoamericana de química (2012)

Elisa Leyva Edgar Moctezuma María del Socorro Santos-Díaz Silvia E. Loredo‐Carrillo Oswaldo Hernández‐González

Se desarrollo una metodologia de quimica verde para la bioreduccion rapida y sencilla de aldehidos aromaticos a alcoholes aromaticos utilizando un extracto de Aloe vera en suspension acuosa. Por medio de radiacion de microondas, esta reaccion se llevo a cabo en un periodo de tiempo muy corto. El procedimiento desarrollado es una ruta alterna para preparar alcoholes aromaticos, los cuales son reactivos muy utilizados en la industria y en la preparacion de cosmeticos

Aloe Vera

Source

Cite

Citations (2)

Function and expression of N-acetyltransferases 1 and 2 are altered in lymphocytes in type 2 diabetes and obesity

Biochemistry and Biophysics Reports (2024)

Víctor Alejandro Paz-Rodríguez Diana Judith Herrera-Vargas Eneida Turiján-Espinoza Miguel Ernesto Martínez-Leija Emmanuel Rivera-López

The cytosolic enzymes N-Acetyl Transferases 1 and 2 (NATs) transfer an acetyl group from acetyl-CoA to a xenobiotic substrate. NATs are regulated at the genetic and epigenetic levels by deacetylase enzymes such as sirtuins. The enzymatic expression of NAT1, NAT2, and SIRT1 was evaluated by flow cytometry, as well as the enzymatic activity of NATs by cell culture and HPLC analysis. Six SNPs were determined through genotyping. T2D patients (n = 29) and healthy subjects (n = 25) with a median age of 57 and 50, respectively, were recruited. An increased enzyme expression and a diminished NAT2 enzymatic activity were found in cells of T2D patients compared to the control group, while NAT1 was negatively correlated with body fat percentage and BMI. In contrast, Sirtuin inhibition increased NAT2 activity, while Sirtuin agonism decreased its activity in both groups. The analysis of NAT2 SNPs showed a higher frequency of rapid acetylation haplotypes in T2D patients compared to the control group, possibly associated as a risk factor for diabetes. The enzymatic expression of CD3+NAT2+ cells was higher in the rapid acetylators group compared to the slow acetylators group. The levels and activity of NAT1 were associated with total cholesterol and triglycerides. Meanwhile, CD3+NAT2+ cells and NAT2 activity levels were associated with HbA1c and glucose levels. The results indicate that NAT2 could be involved in metabolic processes related to the development of T2D, due to its association with glucose levels, HbA1c, and the altered SIRT-NAT axis. NAT1 may be involved with dyslipidaemias in people who are overweight or obese.

Sirtuin 1

Acetyltransferases

Arylamine N-acetyltransferase

10.1016/j.bbrep.2024.101716

Cite

Citations (0)